Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-044398
Filing Date
2025-03-25
Accepted
2025-03-25 16:15:35
Documents
62
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K tennx-20241231.htm   iXBRL 10-K 2527002
2 EX-10.3.5 tennx-ex10_3.htm EX-10.3 53581
3 EX-10.26 tennx-ex10_26.htm EX-10.26 100174
4 EX-19.1 tennx-ex19_1.htm EX-19.1 101173
5 EX-23.1 tennx-ex23_1.htm EX-23.1 3709
6 EX-31.1 tennx-ex31_1.htm EX-31.1 15149
7 EX-31.2 tennx-ex31_2.htm EX-31.2 17031
8 EX-32.1 tennx-ex32_1.htm EX-32.1 8581
9 EX-32.2 tennx-ex32_2.htm EX-32.2 8077
  Complete submission text file 0000950170-25-044398.txt   7887803

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tennx-20241231.xsd EX-101.SCH 854721
64 EXTRACTED XBRL INSTANCE DOCUMENT tennx-20241231_htm.xml XML 1141284
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-34600 | Film No.: 25768485
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)